Shares of PI Industries scale all-time high after robust June results
Shares of PI Industries scale all-time high after robust June results

Shares of PI Industries scale all-time high after robust June results

DSIJ Intelligence Article rating: 3.6

The shares of PI Industries were trading in the green on Wednesday and even rallied to hit an all-time high of Rs 1,966 apiece on BSE after the company reported robust numbers for the first quarter of the financial year 2020-21.

Sensex, Nifty end flat; Sun Pharma Advanced Research leaps by nearly 7 per cent, EID Parry down by nearly 4 per cent
Sensex, Nifty end flat; Sun Pharma Advanced Research leaps by nearly 7 per cent, EID Parry down by nearly 4 per cent

Sensex, Nifty end flat; Sun Pharma Advanced Research leaps by nearly 7 per cent, EID Parry down by nearly 4 per cent

DSIJ Intelligence Article rating: 5.0

Domestic benchmark indices ended the trading day in the negative territory amid a volatile trading session on Wednesday. Sensex closed down marginally by a mere 24.58 points or 0.07 per cent settling at 37,663.33 while Nifty declined by 24.85 points or 0.22 per cent to close at 11,120.10.

Lupin launches Favipiravir at Rs 49 to treat mild to moderate COVID-19 disease
Lupin launches Favipiravir at Rs 49 to treat mild to moderate COVID-19 disease

Lupin launches Favipiravir at Rs 49 to treat mild to moderate COVID-19 disease

Pratik Shastri Article rating: 3.8

The newly-launched drug, which was the need of the hour, would be available in the form of a strip of ten tablets, marketed under the brand name of Covihalt. It will be used to treat patients having a mild to moderate COVID-19 disease.

Zydus Cadila COVID-19 vaccine passes phase 1 human trials
Zydus Cadila COVID-19 vaccine passes phase 1 human trials

Zydus Cadila COVID-19 vaccine passes phase 1 human trials

DSIJ Intelligence Article rating: 4.7

Global pharmaceutical major, Zydus Cadila announced on Wednesday that its plasmid DNA vaccine to prevent COVID-19, namely ZyCoV-D, was found to be well-tolerated and safe in phase 1 clinical trial.

Lupin gets US health regulator nod for Empagliflozin tablets
Lupin gets US health regulator nod for Empagliflozin tablets

Lupin gets US health regulator nod for Empagliflozin tablets

DSIJ Intelligence Article rating: 4.3

Pharma major, Lupin Limited had announced on Tuesday that it has received regulatory approval from United States Food and Drug Administration (USFDA) for its Empagliflozin tablets, 10 mg and 25 mg to market a generic version of Jardiance tablets, 10 mg, and 25 mg, of Boehringer Ingelheim Pharmaceuticals.

Too many funds spoil the fun
Too many funds spoil the fun

Too many funds spoil the fun

DSIJ Intelligence Article rating: 4.0

Most people believe in the phrase, ‘the more the merrier’. However, that might not hold true with mutual funds. Read on to find out why.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 3.5

The market opened in green on August 5, 2020, overall volumes in futures & options currently stand at 2,11,51,827 crore contracts with a turnover of Rs. 14,46,632.04 crore.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 3.5

The market opened in green on August 5, 2020, overall volumes in futures & options currently stand at 2,11,51,827 crore contracts with a turnover of Rs. 14,46,632.04 crore.

RSS
First29102911291229132915291729182919Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR